Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK

Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics
(As of December 31, 2022)
-
$156M
FY’22 Revenue
6% YtY Growth
-
11%
Revenue CAGR
FY’19 – FY’22
-
#1
U.S. Market Share
OA Pain Management
-
$86M
Cash balance
with no debt
Current Investor Presentation
Latest Quarterly Results
Q1 2023 Earnings
Investor Contacts
Primary IR Contact
-
Mark Namaroff
Vice President, Investor Relations, ESG, and Corporate Communications
Anika Therapeutics, Inc.
Phone: (781) 457-9287
Email: investorrelations@anika.com
-
Transfer Agent
American Stock Transfer & Trust Co.
59 Maiden Lane
New York, NY 10038
Phone: (718) 921-8261
Want Alerts? Sign up for alerts and never miss an Investor update!